Skip to main content
. 2024 Sep 19;19(9):e0310641. doi: 10.1371/journal.pone.0310641

Fig 1. CBL mutants are associated with proliferative features, increased BM blast percentage, leukocytosis and splenomegaly.

Fig 1

(A-F) Clinical characteristics of PREACH-M cohort at baseline, stratified based on the detection of CBL mutation. (G) MD-, MP-CMML classification based on WCCα (H) CMML-0, -1, -2 classifications based on BM blast percentageβ. 2016 WHO Classification: αBased on WCC: MD-CMML WCC<13×109/L, MP-CMML WCC>13×109/L. β Based on BM blast %: CMML-0 PB <2%, BM <5%; CMML-1 PB 2–4%, BM 5–9%, CMML-2 PB>5%, BM 10–19%. Bars represent mean ± standard error of mean. Mann-Whitney test used to determine statistical significance, where P<0.05 was statistically significant. [BM bone marrow; WCC white cell count; CRP C-reactive protein; MD-CMML myelodysplastic-CMML; MP-CMML myeloproliferative-CMML, wt wildtype, mut mutant].